article thumbnail

Quality of life in patients with chronic health conditions

World of DTC Marketing

These and other chronic diseases are the leading causes of death and disability in America, and they are also a top driver of health care costs. But what we most often overlook is the effect of chronic health conditions on the quality of life leading to depression and suicide. According to the CDC, in 2012, 25.5%

Patients 199
article thumbnail

Do patients care about accelerated approval drugs?

World of DTC Marketing

The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012. Accelerated Approval was developed in 1992 in response to the HIV/AIDS crisis and has led to expedited drug and biologic approvals in several disease areas across the FDA.

Patients 200
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lessons from the Top 100: Thales [Podcast]

Clarivate

Every year since 2012, Clarivate has identified the Top 100 Global Innovators. These companies and institutions lead the global innovation landscape, contributing new ideas, solving some of the world’s most complex challenges and creating new value. Listen to the podcast.

Leads 98
article thumbnail

Five Years of Forbes | Legacy MEDSearch Ranks on the Forbes Best Executive Recruitment Firms for a Fifth Consecutive Year

Legacy MEDSearch

Leadership includes Joy Celebre (recruiting since 1996, joined in 2008), Carolyn Jones (recruiting since 1995, joined in 2011), Arshad Alam (recruiting since 1995, joined 2017), John White (Talent Sourcing Manager, joined 2012), and Partner Chris Miclot, (joined 2012). “In

article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

Leading the MHRA – a five year journey Professor Graham Cooke, interim chair of the MHRA board, remarked that Dame June’s “leadership of the MHRA over the last five years, particularly during the COVID-19 pandemic, has been exceptional.”

Safety 111
article thumbnail

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

pharmaphorum

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome (SBS), although its share price remains under pressure. Some children are born with an abnormally short small intestine.

Leads 98
article thumbnail

CGT Catapult to bolster new UK life sciences campus

European Pharmaceutical Review

Matthew Durdy, Chief Executive of the CGT Catapult commented: “We are delighted to be involved in the continued development of the leading life sciences cluster in Stevenage. Since its opening in 2012, occupier companies have secured £2.9bn in finance, making the cluster one of the most attractive for investment in biotechnology in the UK.